Added to YB: 2026-06-08
Pitch date: 2026-06-05
LQDA [neutral]
Liquidia Corporation
+33.97%
current return
Author Info
Value with a Catalyst covers long value oriented small and mid- cap investment ideas with a catalyst. Sign up for the newsletter.
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$7.1B
Pitch Price
$64.97
Price Target
N/A
Dividend
N/A
EV/EBITDA
147.57
P/E
327.46
EV/Sales
24.55
Sector
Pharmaceuticals
Category
special_situation
Indirectly Favorable Supreme Court Opinion For Liquidia (Hikma)
LQDA (holding update): Up strong to all-time highs after SCOTUS Hikma opinion, marginally pro-competition/skinny-label, weakening patent strength vs UTHR's '327. May give Yutrepia more operational freedom for PH-ILD even if patent upheld. Likely unblocks Judge Andrews ruling within weeks, removing legal overhang. Royalty risk remains but valuation may offset.
Read full article (2 min)